Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in TumorNeil L. Spector(Tennessee Oncology), Kevin M. Koch(GlaxoSmithKline (United States))PLoS ONENovember 16, 201510.1371/journal.pone.0142845Cited by 31SaveCiteExport RISWatch citationsRelated PapersStudy of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies|Journal of Clinical Oncology|2005|364